Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENB-006
- Development stage
- Preclinical
- Lead developer
- ENB Therapeutics
- Modality
- Small Molecules
01
Overview
ENB-006 is a preclinical-stage small molecule drug candidate being developed by ENB Therapeutics. It is part of a pipeline focused on modulating the tumor microenvironment to improve the efficacy of immune checkpoint inhibitors. Based on the company's core technology platform, ENB-006 is likely designed to target the Endothelin B Receptor (ETBR). Antagonism of ETBR on tumor vascular endothelium is intended to downregulate ICAM-1, thereby removing the 'barrier' that prevents T-cells from infiltrating the tumor. This mechanism aims to convert 'cold' tumors into 'hot' tumors, potentially overcoming resistance to standard immunotherapies in various solid tumors.
02
Targets
EDNRB (Endothelin receptor type B)
Beyond the preview
Go deeper on ENB-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENB-006.